Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: A multicenter phase II trial

Lung Cancer

Volumn 55, Issue 1, 2007, Pages 101-107

  Pallis, A G ^a   Christofillakis, Ch ^b   Tselepatiotis, E ^c   Agelaki, S ^a   Vamvakas, L ^a   Souglakos, J ^a   Vardakis, N ^a   Kalykaki, A ^a   Kotsakis, A ^a   Argiraki, A ^c   Mavroudis, D ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b 401 Military Hospital of Athens   (Greece)

^c KAT HOSPITAL   (Greece)

Author keywords

Docetaxel; Gefitinib; NSCLC; Sequential therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DIMETINDENE; DOCETAXEL; DOXYCYCLINE; GEFITINIB; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ACNE; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; SMOKING; SURVIVAL ANALYSIS; TAXOIDS;

EID: 33845935220     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.08.019     Document Type: Article

References (29)

1. Ginsberg R.J., Vokes E.E., and Raben A. Non small cell lung cancer. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Principles and practice in oncology. 5th ed. (1997), Lippincott-Raven, Philadelphia 858-911
2. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311 (1995) 899-909
3. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18 12 (2000) 2354-2362
4. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 10 (2000) 2095-2103
5. Sedlacek H.H. Kinase inhibitors in cancer therapy: a look ahead. Drugs 59 3 (2000) 435-476
6. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., and Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3 4 (1997) 515-522
7. Brabender J., Danenberg K.D., Metzger R., Schneider P.M., Park J., Salonga D., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7 7 (2001) 1850-1855
8. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 12 (2003) 2237-2246
9. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 16 (2003) 2149-2158
10. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 5 (2004) 777-784
11. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 5 (2004) 785-794
12. Day R.S. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 46 8 (1986) 3876-3885
13. Norton L., and Simon R.G. Tumor size, sensitivity to therapy and design of treatment schedules. Cancer Treat Rep 61 (1977) 1307-1317
14. Hainsworth J.D., and Greco F.A. The role of weekly docetaxel in the treatment of advanced non-small-cell lung cancer. Clin Lung Cancer 3 Suppl. 2 (2002) S17-S22
15. Hainsworth J.D., Burris III H.A., Litchy S., Morrissey L.H., Barton J.H., Bradof J.E., et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A minnie pearl cancer research network phase II trial. Cancer 89 2 (2000) 328-333
16. Gervais R., Ducolone A., Breton J.L., Braun D., Lebeau B., Vaylet F., et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16 1 (2005) 90-96
17. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 1 (1981) 207-214
18. Cancer Therapy Evaluation Program. Common toxicity criteria. Version 2.0. DCTD, NCI, NIH, DHHS, 1998.
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 1 (1989) 1-10
20. Simon R. How large should a phase II trial of a new drug be?. Cancer Treat Rep 71 11 (1987) 1079-1085
21. Collet D. Modelling survival data in medical research. 3rd ed. (1994), Blackwell Scientific, Oxford
22. Altman G.D. Practical statistics for medical research (1991), Chapman & Hall, London, UK
23. Carney D.N. Lung cancer-time to move on from chemotherapy. N Engl J Med 346 2 (2002) 126-128
24. Socinski M.A., Schell M.J., Peterman A., Bakri K., Yates S., Gitten R., et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20 5 (2002) 1335-1343
25. Smith I.E., O'Brien M.E., Talbot D.C., Nicolson M.C., Mansi J.L., Hickish T.F., et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19 5 (2001) 1336-1343
26. Schuette W., Nagel S., Blankenburg T., Lautenschlaeger C., Hans K., Schmidt E.W., et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23 33 (2005) 8389-8395
27. Souquet P.J., Tan E.H., Rodrigues P.J., Van K.R., Price A., Gatzemeier U., et al. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 13 12 (2002) 1853-1861
28. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 21 (2004) 2129-2139
29. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 5676 (2004) 1497-1500